{"id":"tak-816-dpt-takeda","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This results in decreased glucose levels in the blood, which can help to improve glycemic control in patients with diabetes.","oneSentence":"TAK-816 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:28.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01379846","phase":"PHASE3","title":"Study of TAK-816 in Healthy Infants","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-06","conditions":"Immunization","enrollment":416}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vaxem Hib"],"phase":"phase_3","status":"active","brandName":"TAK-816+ DPT-TAKEDA","genericName":"TAK-816+ DPT-TAKEDA","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TAK-816+ DPT-TAKEDA is being studied as an intervention for immunization in healthy infants. The study, NCT01379846, is a randomized, double-blind, multicenter trial sponsored by Takeda.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}